Tempest Partners with Senlang to Advance In Vivo CAR-T for Autoimmune Diseases
TPST is trading near its 52-week low of $0.93 (7.5% above the low).
Summary
Tempest announced a collaboration with Hebei Senlang Biotechnology to develop TPST-4003, its next-generation in vivo CAR-T therapy targeting CD7. The partnership kicks off with an investigator-initiated trial in China for myasthenia gravis and multiple sclerosis, with first patient dosing expected in Q4 2026. Senlang brings deep CD7 CAR-T clinical expertise and gets an exclusive option to negotiate a China license. This is a meaningful step for Tempest, which has been under severe financial strain—recently reporting a $27.7M quarterly loss and a going-concern warning. The collaboration provides a capital-efficient path to first-in-human data, potentially validating the platform without immediate large-scale spending. Initial safety and pharmacodynamic data could arrive as early as H1 2027, offering a near-term catalyst for a company with a sub-$1 stock price and a market cap around $15M.
At the time of this announcement, TPST was trading at $1.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.2M. The 52-week trading range was $0.93 to $12.23. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.